Gold bars to be exempt from tariffs, White House clarifies
HOUSTON - Healthcare operations software provider symplr has acquired the Smart Square scheduling software from AMN Healthcare (NYSE:AMN), according to a press release statement issued Wednesday. AMN Healthcare, currently trading at $21.99, has seen its shares decline over 55% in the past year, according to InvestingPro data. The company appears undervalued based on InvestingPro’s Fair Value analysis.
The acquisition aims to enhance symplr’s workforce management capabilities by integrating Smart Square’s AI-driven scheduling technology into its operations platform. Smart Square offers predictive analytics, real-time staffing adjustments, open-shift management, and nurse competency integration features. This transaction comes as AMN Healthcare maintains a solid financial position with a current ratio of 1.08 and generates substantial free cash flow, as revealed by InvestingPro analysis.
"A critical way for hospitals and health systems to unlock greater value from their technology is to arm them with intelligent, purpose-built solutions," said BJ Schaknowski, CEO of symplr.
The deal brings together two Best in KLAS solutions, as symplr’s Time and Attendance technology has earned recognition in the timekeeping category for over two decades, while Smart Square received the 2025 Best in KLAS award for Scheduling: Nurse & Staff.
As part of the transaction, symplr and AMN Healthcare have established a commercial partnership to combine symplr’s operational technology with AMN’s healthcare workforce solutions.
"Healthcare organizations are navigating unprecedented workforce complexity. This deal accelerates our focus on workforce planning, analytics and AI with our WorkWise platform, while seamlessly integrating with scheduling and operational tools through strategic technology partnerships like symplr," said Cary Grace, President and CEO at AMN Healthcare.
symplr is backed by Clearlake Capital Group and Charlesbank Capital Partners. The company’s software is currently used in 9 of 10 U.S. hospitals and more than 400 U.S. health plans, according to the press release.
Financial terms of the acquisition were not disclosed. AMN Healthcare is scheduled to report its next earnings on July 31, 2025, with analysts expecting a return to profitability this year despite recent challenges. For comprehensive analysis of AMN Healthcare’s financial health and future prospects, investors can access the detailed Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert insights and actionable intelligence.
In other recent news, AMN Healthcare reported its Q1 2025 financial results with revenue reaching $690 million, surpassing expectations by 10%. Despite a year-over-year decline in adjusted EPS from $0.97 to $0.45, the earnings exceeded market forecasts. The company achieved a debt reduction of $60 million and emphasized new technology rollouts and operational efficiency improvements. However, Moody’s downgraded AMN Healthcare’s corporate family rating to Ba3 from Ba2, citing deteriorating credit metrics and a structural decline in nurse staffing demand. The outlook was revised to negative, despite AMN’s strong liquidity and leading position in the temporary healthcare staffing industry. Additionally, Celia Huber was elected to AMN Healthcare’s Board of Directors, bringing over 30 years of experience in healthcare strategy and governance. These developments highlight the company’s mixed financial landscape, with strong liquidity and strategic advancements counterbalanced by credit challenges and industry pressures.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.